This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Calendar: Key Dates for February

BOSTON, Mass. ( TheStreet) -- A calendar of important, potentially stock-moving biotech events for February:

Feb 1:
Discovery Labs (DSCO): Surfaxin regulatory update conference call.
Earnings: Biogen Idec (BIIB), Pfizer (PFE).

Feb. 2
Earnings: Sangamo BioSciences (SGMO), Viropharma (VPHM).

Feb 3:
Alimera Sciences (ALIM - Get Report): 36-month results from phase III study of Iluvien in diabetic macular edema.
Earnings: Alkermes (ALKS), GlaxoSmithKline (GSK), Avanir Pharmaceuticals (AVNR), Merck (MRK), Vertex Pharmaceuticals (VRTX),

Feb. 8:
Adeona Pharmaceuticals (AEN) investor/analyst day.
Earnings: Seattle Genetics (SGEN), Rigel Pharmaceuticals (RIGL), Teva (TEVA),

Feb. 9:
Earnings: Sanofi-Aventis (SNY)

Feb. 10:
Earnings: Alexion Pharmaceuticals (ALXN), Cephalon (CEPH), Incyte Pharmaceuticals (INCY), MannKind (MNKD), Momenta Pharmaceuticals (NNTA).

Feb 14-15:
BIO CEO & Investor Conference, New York City.

Feb 15:
Expiration of Sanofi-Aventis' $69-a-share tender offer for Genzyme (GENZ).

Feb. 16:
Earnings: Genzyme

Feb. 17:
Exelixis (EXEL): Presentation of updated cabozantinib (XL184) data in prostate cancer at ASCO GU symposium
Earnings: Biomarin Pharmaceuticals (BMRN), Acorda Therapeutics (ACOR)

Feb. 22:
Earnings: Questcor Pharmaceuticals (QCOR)

Feb 25:
Pfizer and Protalix Therapeutics (PLX - Get Report): FDA approval decision date for Uplyso in Gaucher's disease.

Other potential February events
Idenix Pharmaceuticals (IDIX): FDA decision on lifting clinical hold on hepatitis C drugs IDX184 and IDX320.
Amylin Pharmaceuticals (AMLN), Alkermes, Eli Lilly (LLY): Start of a Bydureon Qt study.

Source: Company reports, BioMedTracker.com

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ALIM $4.70 3.10%
AVNR $16.96 0.00%
EXEL $5.58 2.50%
IDIX $24.50 0.20%
PLX $1.73 1.20%

Markets

Chart of I:DJI
DOW 17,551.90 +111.31 0.64%
S&P 500 2,082.65 +15.01 0.73%
NASDAQ 5,062.72 +22.9440 0.46%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs